Loading...
GRPH logo

Graphite Bio, Inc.NasdaqGM:GRPH Stock Report

Market Cap US$190.4m
Share Price
n/a
My Fair Value
n/a
1Y861.6%
7D539.7%
1D
Portfolio Value
​
View

Graphite Bio, Inc.

NasdaqGM:GRPH Stock Report

Market Cap: US$190.4m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Graphite Bio (GRPH) Stock Overview

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. More details

GRPH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years


GRPH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Graphite Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Graphite Bio
Historical stock prices
Current Share PriceUS$22.26
52 Week HighUS$22.62
52 Week LowUS$2.01
Beta0.20
1 Month Change654.58%
3 Month Change831.38%
1 Year Change861.56%
3 Year Changen/a
5 Year Changen/a
Change since IPO20.32%

Recent News & Updates

Analysis Article • Sep 20

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Recent updates

Analysis Article • Sep 20

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Jun 02

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Feb 01

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Oct 05

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 11

Graphite Bio doses first patient with GPH101 for sickle cell disease

Graphite Bio (NASDAQ:GRPH) is trading 2.1% higher after the company said it had finished dosing the first patient with its drug, GPH101, now called nulabeglogene autogedtemcel, in the company’s Phase 1/2 trial to treat people with sickle cell disease (SCD). The drug, Nula-celm is a gene editing therapy designed to directly correct the genetic mutation that causes SCD. "We believe nula-cel could be a definitive cure for sickle cell disease, with the potential to address all complications associated with this life-threatening disease. We look forward to reporting initial proof-of-concept data from the CEDAR trial in mid-2023," the company said. The trial will be conducted in about 15 patients with severe SCD. The trial is currently enrolling patients at multiple sites in the United States.
Analysis Article • Jun 22

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • May 25

Graphite Bio: Selling For Much Less Than Net Cash

Shares of Graphite Bio are down some 85% from their June 2021 IPO pricing, as its first-ever clinical trial for the treatment of sickle cell disease experienced a six-month delay. The company’s potentially curative technology builds on CRISPR Therapeutics by pasting a DNA template into the target gene after it has been cut. With no actionable data likely forthcoming until mid-2023 but trading at a significant discount to cash, the recent insider buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Seeking Alpha • Nov 18

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio Initiated the phase 1/2 CEDAR trial using GPH101 for a potential curative treatment of patients with severe sickle-cell disease. First patient in phase 1/2 CEDAR trial will be dosed in the 1st half of 2022 and the first set of results are expected in the 2nd half of 2022. It is estimated that the Sickle Cell Disease market is estimated to be worth $5.5 billion by 2023. If proof of concept achieved for GPH101 in Sickle-cell disease, then other indications to be tackled are Gaucher Disease and XSCID; IND filings for one of these not anticipated until mid-2023.
Analysis Article • Sep 25

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Aug 30

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Graphite Bio is a clinical-stage development biotech making use of CRISPR-based gene-editing therapy to develop a cure for sickle cell disease. Now, a biotechnology journal has published an adverse report on the safety of CRISPR-Cas9. As a result, the shares dipped, but have recovered partly. I make sense of the implications by going deeper into the report and, based on my assessment, the biotech's therapy has a differentiated gene correction approach. Operating in a highly specialized medical field and combating a life-threatening disease, the company is a buy at current prices, but the road towards commercialization will be a long and tortuous one.

Shareholder Returns

GRPHUS BiotechsUS Market
7D539.7%1.2%1.6%
1Y861.6%35.1%28.2%

Return vs Industry: GRPH exceeded the US Biotechs industry which returned 12.6% over the past year.

Return vs Market: GRPH exceeded the US Market which returned 31.2% over the past year.

Price Volatility

Is GRPH's price volatile compared to industry and market?
GRPH volatility
GRPH Average Weekly Movement166.3%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: GRPH's share price has been volatile over the past 3 months.

Volatility Over Time: GRPH's weekly volatility has increased from 82% to 166% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20176Kim Drapkingraphitebio.com

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.

Graphite Bio, Inc. Fundamentals Summary

How do Graphite Bio's earnings and revenue compare to its market cap?
GRPH fundamental statistics
Market capUS$190.43m
Earnings (TTM)-US$124.65m
Revenue (TTM)n/a
0.0x
P/S Ratio
-10.4x
P/E Ratio

Is GRPH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GRPH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$124.65m
Earnings-US$124.65m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.14
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did GRPH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/03/21 01:09
End of Day Share Price 2024/03/21 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Graphite Bio, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Konstantinos BiliourisBMO Capital Markets Equity Research
Gregory HarrisonBofA Global Research
Yun ZhongBTIG